CCA
AZN icon

Catalyst Capital Advisors’s AstraZeneca AZN Stock Holding History

Catalyst Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-82
Closed -$15K – 371
2025
Q4 		$15K Sell
82
-65
-44% -$11.4K ﹤0.01% 358
2025
Q3 		$22.6K Sell
147
-33
-18% -$5K ﹤0.01% 422
2025
Q2 		$25.2K Sell
180
-45
-20% -$6.31K ﹤0.01% 430
2025
Q1 		$33K Hold
225
– – ﹤0.01% 395
2024
Q4 		$29.4K Sell
225
-17,875
-99% -$2.5M ﹤0.01% 411
2024
Q3 		$2.82M Buy
18,100
+17,821
+6,387% +$2.88M 0.06% 96
2024
Q2 		$43.5K Buy
279
+8
+3% +$1.2K ﹤0.01% 260
2024
Q1 		$36.7K Buy
+271
New +$35.9K ﹤0.01% 271
2023
Q4 		– Sell
-219
Closed -$29.7K – 379
2023
Q3 		$29.7K Buy
219
+53
+32% +$7.24K ﹤0.01% 280
2023
Q2 		$23.8K Sell
166
-8
-5% -$1.18K ﹤0.01% 303
2023
Q1 		$24.1K Sell
174
-65
-27% -$8.74K ﹤0.01% 289
2022
Q4 		$32.3K Sell
239
-36,922
-99% -$4.63M ﹤0.01% 273
2022
Q3 		$4.08M Sell
37,161
-917
-2% -$116K 0.15% 68
2022
Q2 		$5.03M Buy
38,078
+37,613
+8,089% +$4.94M 0.21% 57
2022
Q1 		$62K Buy
+465
New +$55.8K ﹤0.01% 289

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Catalyst Capital Advisors's AZN Position: Q1 2026 in Review

Catalyst Capital Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 82 shares — an estimated $15K sold.

Catalyst Capital Advisors first reported a position in AZN in Q1 2022 and held it in 15 quarters. The position peaked at $5.03M in Q2 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Catalyst Capital Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Catalyst Capital Advisors sold 82 AstraZeneca shares in Q1 2026, an estimated $15K.
  • Catalyst Capital Advisors first reported a position in AstraZeneca in Q1 2022 and held it in 15 quarters.
  • Catalyst Capital Advisors's AstraZeneca position peaked at $5.03M in Q2 2022.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Catalyst Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.